研究方向：

致力于肿瘤代谢与靶向研究，重点关注关键癌/抑癌蛋白翻译后修饰的调控机制，以期开发出新的肿瘤靶向策略

主要论文：

1. Rongfu Tu^#, Zhi Chen^#, Qing Bao#, Hudan Liu, Guoliang Qing ^*. Crosstalk between oncogenic MYC and noncoding RNAs in cancer.  Seminars in Cancer Biology, 2020.
2. Rongfu Tu ^#, Wenqian Kang^#, Mengjie Yang,  Liyuan Wang, Qing Bao, Zhi Chen, Yang Dong, Jingchao Wang, Jue Jiang, Hudan Liu, Guoliang Qing^*. USP29 coordinates MYC and HIF1α stabilization to promote tumor metabolism and progression. Oncogene, 2021.
3. Rongfu Tu^#,*, Junpeng Ma ^#, Yule Chen^#, Ye Kang, Doudou Ren, Zeqiong Cai, Ru Zhang, Yiwen Pan, Yijia Liu, Yanyan Da, Yao Xu, Yahuan Yu, Donghai Wang, Jingchao Wang, Yang Dong, Xinlan Lu, Chengsheng Zhang ^* . USP7 depletion potentiates HIF2α degradation and inhibits clear cell renal cell carcinoma progression. Cell Death & Disease, 2024.
4. Rongfu Tu^#, Wenqian Kang^#, XuefeiYang, Qi Zhang, Xiaoyu Xie, Wenbin Liu ,JinxiangZhang, Xiao-Dong Zhang, Hui Wang^* , Run-Lei Du^* . USP49 participates in the DNA damage response by forming a positive feedback loop with p53. Cell Death & Disease, 2018.
5. Rongfu Tu ^#,*, Ye Kang ^#, Yiwen Pan ^#, Yanyan Da ^#, Doudou Ren, Ru Zhang, Zeqiong Cai, Yijia Liu, Jiao Xu, Junpeng Ma, Zhiyong Zhou, Shupeng Yin, Xiaozhuang Li, Peng Zhang, Qi Zhang, Jingchao Wang, Xinlan Lu, Chengsheng Zhang^*.USP29 activation mediated by FUBP1 promotes AURKB stability and oncogenic functions in gastric cancer. Cancer cell international, 2024.
6. Rongfu Tu^#, Junpeng Ma^#, Peng Zhang^#, Ye Kang, Xiaofan Xiong, Junsheng Zhu, Miao Li, Chengsheng Zhang^*. The emerging roles of deubiquitylating enzymes in cancer metabolism and targeted therapy. Cancer cell international，2022.
7. Ye Kang^#, Yahuan Yu^#, Yijia Liu^#, Yiwen Pan, Ru Zhang, Doudou Ren, Zeqiong Cai, Junpeng Ma, Xiaofan Xiong, Qi Zhang, Chengsheng Zhang^* & Rongfu Tu^*.Identification of USP29 as a key regulator of nucleotide biosynthesis in neuroblastoma through integrative analysis of multi-omics data. Cancer Biology & Therapy, 2023.
8. Ru Zhang^#, Zeqiong Cai^#, Doudou Ren^#, Ye Kang, Qi Zhang, Xinlan Lu^*, Rongfu Tu^*. The emerging role of USP29 in cancer and other diseases. Cell Biochemistry & Function, 2024.
9. Rongfu Tu^#, Wenqian Kang^#, Ye Kang, Peng Zhang, Xiaofan Xiong,  Junpeng Ma, Run-Lei Du*, Chengsheng Zhang* . c-MYC-USP49-BAG2 axis promotes proliferation and chemoresistance of colorectal cancer cells in vitro. Biochem Biophys Res Commun. 2022..
10. Yang Dong, Rongfu Tu, Hudan Liu, Guoliang Qing^*. Regulation of cancer cell metabolism: oncogenic MYC in the driver's seat. Signal Transduction and Targeted Therapy, 2020.
11. Zhi Chen^# , Chan Chen^#, Lei Xiao^#, Rongfu Tu, Miaomiao, Donghai Wang, Wenqian Kang, Meng Han, Hao Huang, Hudan Liu^*, Bing Zhao^*, Guoliang Qing^*. HILPS, a long noncoding RNA essential for global oxygen sensing in humans. Science Advances, 2023.
12. Qi Zhang^#, Ze-Yan Zhang^#, Huan Du, Shang-Ze Li, Rongfu Tu, Yi-fan Jia, Zhe Zheng, Xue-Min Song, Run-Lei Du, Xiao-Dong Zhang^*. DUB3 deubiquitinates and stabilizes NRF2 in chemotherapy resistance of colorectal cancer. Cell death and differentiation. 2019.

项目信息：

1. 中央高校基本科研业务费，xzy012023112，干预USP7 治疗肾透明细胞癌的分子机制研究，2023 年01 月至2025 年12 月，10万元，在研，主持
2. 国家自然科学基金委员会，青年科学基金项目，82203282，FUBP1-USP29-AURKB轴促进胃癌发生发展的功能与机制研究，2023-01-01至2025-12-31，30万元，在研，主持
3. 国家自然科学基金委员会，重点项目，81830084，干预关键代谢靶点协同癌蛋白MYC选择性致死肿瘤细胞的分子机制研究，2019-01-01至2023-12-31，297万元，结题，参与
4. 国家自然科学基金委员会，面上项目，82373726，靶向Bcr-Abl底物结合位点的新型多肽类抑制剂设计合成及其抗CML活性研究，2024-01-01至2027-12-31，49万元，在研，参与
5. 国家自然科学基金青年项目，31501148， NLK参与调控NRF2信号通路及其介导的大肠癌肿瘤细胞耐药性的研究，2016-01 至 2018-12，20万元，已结题，参与

专利：

1. 卿国良，陈智，涂容福，王敬超；一种乳腺癌标志物及应用, 2020-10-27, 中国, CN202011161084.9 (专利)